vs
Side-by-side financial comparison of Autolus Therapeutics plc (AUTL) and Orchid Island Capital, Inc. (ORC). Click either name above to swap in a different company.
Orchid Island Capital, Inc. is the larger business by last-quarter revenue ($38.5M vs $21.2M, roughly 1.8× Autolus Therapeutics plc). Orchid Island Capital, Inc. runs the higher net margin — 268.7% vs -373.3%, a 642.0% gap on every dollar of revenue.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
Orchid Island Capital, Inc. is a U.S.-based specialty finance company operating as a real estate investment trust. It primarily invests in residential mortgage-backed securities, including agency and non-agency products, targeting consistent risk-adjusted returns for its investors across U.S. fixed income markets.
AUTL vs ORC — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.2M | $38.5M |
| Net Profit | $-79.1M | $103.4M |
| Gross Margin | — | — |
| Operating Margin | -337.9% | — |
| Net Margin | -373.3% | 268.7% |
| Revenue YoY | — | 372.6% |
| Net Profit YoY | 3.6% | 1764.9% |
| EPS (diluted) | $-0.30 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $38.5M | ||
| Q3 25 | $21.2M | $26.9M | ||
| Q2 25 | $20.9M | $23.2M | ||
| Q1 25 | $9.0M | $19.7M | ||
| Q3 24 | $0 | $340.0K | ||
| Q2 24 | $0 | $-697.0K | ||
| Q1 24 | $10.1M | $-2.5M | ||
| Q4 22 | — | $2.4M |
| Q4 25 | — | $103.4M | ||
| Q3 25 | $-79.1M | $72.1M | ||
| Q2 25 | $-47.9M | $-33.6M | ||
| Q1 25 | $-70.2M | $17.1M | ||
| Q3 24 | $-82.1M | $17.3M | ||
| Q2 24 | $-58.3M | $-5.0M | ||
| Q1 24 | $-52.7M | $19.8M | ||
| Q4 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -337.9% | — | ||
| Q2 25 | -292.6% | — | ||
| Q1 25 | -726.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -384.1% | — | ||
| Q4 22 | — | — |
| Q4 25 | — | 268.7% | ||
| Q3 25 | -373.3% | 267.8% | ||
| Q2 25 | -229.0% | -145.0% | ||
| Q1 25 | -781.1% | 86.9% | ||
| Q3 24 | — | 5094.1% | ||
| Q2 24 | — | 714.3% | ||
| Q1 24 | -522.1% | -794.2% | ||
| Q4 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | $-0.30 | — | ||
| Q2 25 | $-0.18 | — | ||
| Q1 25 | $-0.26 | — | ||
| Q3 24 | $-0.31 | — | ||
| Q2 24 | $-0.22 | — | ||
| Q1 24 | $-0.24 | — | ||
| Q4 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.1M | $665.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $265.5M | $1.4B |
| Total Assets | $661.9M | $11.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $665.9M | ||
| Q3 25 | $86.1M | $583.9M | ||
| Q2 25 | $123.8M | $440.8M | ||
| Q1 25 | $95.8M | $396.4M | ||
| Q3 24 | $657.1M | $322.1M | ||
| Q2 24 | $705.9M | $241.0M | ||
| Q1 24 | $758.5M | $190.4M | ||
| Q4 22 | — | $205.7M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | $265.5M | $1.1B | ||
| Q2 25 | $346.5M | $912.0M | ||
| Q1 25 | $371.1M | $855.9M | ||
| Q3 24 | $477.0M | $656.0M | ||
| Q2 24 | $527.8M | $555.9M | ||
| Q1 24 | $582.0M | $481.6M | ||
| Q4 22 | — | $438.8M |
| Q4 25 | — | $11.7B | ||
| Q3 25 | $661.9M | $9.1B | ||
| Q2 25 | $721.0M | $7.6B | ||
| Q1 25 | $746.3M | $7.3B | ||
| Q3 24 | $827.5M | $5.9B | ||
| Q2 24 | $853.6M | $4.9B | ||
| Q1 24 | $901.4M | $4.2B | ||
| Q4 22 | — | $3.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.9M | $120.4M |
| Free Cash FlowOCF − Capex | $-72.3M | — |
| FCF MarginFCF / Revenue | -341.2% | — |
| Capex IntensityCapex / Revenue | 20.8% | — |
| Cash ConversionOCF / Net Profit | — | 1.16× |
| TTM Free Cash FlowTrailing 4 quarters | $-322.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $120.4M | ||
| Q3 25 | $-67.9M | $28.0M | ||
| Q2 25 | $-72.8M | $18.4M | ||
| Q1 25 | $-75.6M | $25.8M | ||
| Q3 24 | $-76.7M | $-14.8M | ||
| Q2 24 | $-51.1M | $19.3M | ||
| Q1 24 | $-40.5M | $45.0M | ||
| Q4 22 | — | $289.4M |
| Q4 25 | — | — | ||
| Q3 25 | $-72.3M | — | ||
| Q2 25 | $-80.1M | — | ||
| Q1 25 | $-83.8M | — | ||
| Q3 24 | $-86.3M | — | ||
| Q2 24 | $-51.9M | — | ||
| Q1 24 | $-41.0M | — | ||
| Q4 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -341.2% | — | ||
| Q2 25 | -382.6% | — | ||
| Q1 25 | -933.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -406.8% | — | ||
| Q4 22 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 20.8% | — | ||
| Q2 25 | 34.8% | — | ||
| Q1 25 | 91.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 5.3% | — | ||
| Q4 22 | — | — |
| Q4 25 | — | 1.16× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.51× | ||
| Q3 24 | — | -0.86× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.28× | ||
| Q4 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
